MedTrace Logo

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

NCT02592486 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2019-01-31

Study results available
· View outcomes & findings →

Summary

The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza vaccine and pneumococcal vaccine with that of separate administration.

Conditions

Interventions

BIOLOGICAL

Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®

Injections of pneumococcal vaccine and influenza vaccine simultaneously.

BIOLOGICAL

Sequential administration of Pneumovax NP® and Fluvic HA syringe®

Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.

Sponsors & Collaborators

  • PPD Development, LP

    collaborator INDUSTRY

  • Osaka University

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Kameda Medical Center

    lead OTHER

Principal Investigators

  • Kei Nakashima, MD · Department of Pulmonary Medicine, Kameda Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-03-31
Completion
2016-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02592486 on ClinicalTrials.gov